A Private Equity firm based in the western United States The firm is currently making investments out of its vintage 2014 healthcare centric fund. The firm looks to make primarily growth equity investments ranging from $5-$30 million with most investments falling in the $10-$30 million dollar range. The firm is willing to review opportunities from around the Globe.

The firm currently interested broadly in the healthcare space including Medical Technology, Therapeutics, Diagnostics, Laboratory Equipment, Healthcare IT and R&D services. For medical technology the firm is looking for companies that have at least an alpha prototype and have some efficacy data.  For companies working with therapeutics the firm is looking for assets that are in Phase II of clinical trials and will only consider companies in Phase I if they have efficacy data. The firm generally does not look for companies in the cardiovascular space and they are open to orphan indications. The firm is also open to investing in companies that have products already on the market.

The firm looks for a strong management team to be in place and is open to invest in both private and publically held companies. For companies that are privately held the firm generally looks to take a board seat.

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective.  Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest).  While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.

An angel group with offices throughout the United States is looking for companies with female founder or CEO, or with women in other C-level positions. The group prefers to invest in companies with a valuation under $5 million; the group’s first-round equity investments generally range from $ 0.25 million to $2 million. The group invests in companies based across the US and Canada.

The group is currently looking for new investment opportunities in the life science space.  Within the life science sector, the group is highly opportunistic and inclusive when considering opportunities. The group will consider any indication or technology, but as they prefer to invest in products that have an addressable market of over $1 billion, the group is more interested in large marketplaces such as the cardiovascular space than in rare diseases.

In terms of validation, the group prefers to invest in device companies with positive in vitro data and ideally in vivo data; diagnostic companies with strong retrospective and ideally prospective, data; and therapeutics companies with data showing efficacy in animal models.  As the group is interested in products with a shorter path to market, the group primarily invests in healthcare IT (including software-based diagnostic platforms) and medical devices.

The group only backs privately held companies in which women occupy key roles as managers, founders or equity owners, and prefers to back management teams with a strong scientific background.  The group is looking for life science companies with protectable IP, articulated pathways for regulatory and payer approval, clear milestones, and in which the amount of capital required to reach the marketplace can be clearly stated.

A European Venture Capital firm is looking to invest exclusively invests in early stage life science companies. The firm makes seed and early stage investments typically in the Series A round and can allocate €1-10M initially and an additional €10-15M in a follow-on investment per company. The firm typically co-invests with other institutional investors for larger investments. The firm is actively seeking opportunities throughout United States and Europe.

The firm is currently looking for biotech therapeutics, medical devices, and industrial biotech. For therapeutics, the firm invests in small molecule and biologics as well as cell and gene therapy. The firm is open to all indications as well as orphan indications. The firm will consider products as early as 24-month from IND through to Phase II. For medical devices, the firm seeks paradigm-shifting technologies that can reach a human proof-of-concept stage in a relatively short period of time.

The firm prefers to lead or co-lead an investment and generally require a board seat in its portfolio companies.

A family office based in the north eastern United States is dedicated to accelerating the translation of new and innovative programs in the CV and stroke areas. The firm makes equity and convertible note investments of approximately $1 million into companies that are targeting cardiovascular and neurovascular diseases. The firm invests in privately held companies at both the seed and venture stage and is currently invests in 4-5 companies per year. The firm operates under an evergreen structure and is constantly seeking new investment opportunities. While the firm will consider investments around the globe, the firm is keen to add companies based in Europe to its portfolio. The firm is currently looking for companies in both the Biotech Therapeutic & Diagnostics and Medtech sectors. The firm’s focus is on companies developing technologies for cardiovascular, neurovascular and metabolic diseases (diabetes, dyslipidemia and obesity). The firm looks to invest in companies where the investment will help move the company to an inflection point necessary for the next and larger investment round.  The firm is only willing to allocate to companies who have a clear impact on patient therapy and/or standard of care, an adequate level of IP protection, well-defined use of proceeds with quantifiable and achievable milestones, and a clear understanding of the next round of fundraising needs including how much and likely sources.

An angel network based out of the North Eastern United States looks to make equity investments in early-stage and selectively seed stage life science companies ranging from $.5 – $1.5 million. The firm is also open to syndication on larger deals will consider opportunities throughout the United States and Canada. The firm plans to allocate to 10 new companies over the next year.

The group is open to sectors in the life science space including therapeutics, diagnostics and medical devices. The firm is generally opportunistic in terms of technology type, indication and is open to both small molecules and biologics. The firm is comfortable in investing in series A, B, C, or D rounds and is willing to invest in technologies that are pre-clinical or in early clinical trials.

The is most interested in investing in companies with experienced management teams though they also consider spinouts from universities in certain situations. The firm looks to invest in privately held companies and generally takes a seat on the company’s board.

A venture capital company based on the West Coast of the United States is currently making investments out of its second fund. The firm looks to make seed and series A investments ranging from $50,000 to $5 million in the initial round with additional capital reserved for follow on financing pending the company has reached positive milestones. The firm is actively seeking new investments and is looking globally for opportunities.

The firm is currently looking for companies in sectors of Healthcare IT, Big Data Analytics, Bioinformatics and Genomics with special interest for applications of personalized medicine and predictive diagnostics. Though the firm has made medical device investments in the past, the firm is generally shifting away from devices that enable treatment and is focusing on software and software enabled devices that are used to generate and/or analyze biological data. The firm is especially interested in scalable platforms that have the potential for use in more than one indication or aspect of healthcare. The firm is generally open in terms of indication though they have invested in the past with companies working with chronic disease such as cancer as well as behavioral health and pain.

The firm is looking for privately held companies with experienced management teams. The firm looks to help the companies pivot and develop their technologies adding strategic value in addition to just capital.